Modality
Multispecific
MOA
IL-13i
Target
Nectin-4
Pathway
STING
NMOSD
Development Pipeline
Preclinical
Jan 2022
→ Aug 2027
PreclinicalCurrent
NCT05194971
2,850 pts·NMOSD
2022-01→2027-08·Active
2,850 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-271.4y awayInterim· NMOSD
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2027-08-27 · 1.4y away
NMOSD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05194971 | Preclinical | NMOSD | Active | 2850 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 |